[go: up one dir, main page]

WO2011098578A3 - Liposome system for ocular administration - Google Patents

Liposome system for ocular administration Download PDF

Info

Publication number
WO2011098578A3
WO2011098578A3 PCT/EP2011/052061 EP2011052061W WO2011098578A3 WO 2011098578 A3 WO2011098578 A3 WO 2011098578A3 EP 2011052061 W EP2011052061 W EP 2011052061W WO 2011098578 A3 WO2011098578 A3 WO 2011098578A3
Authority
WO
WIPO (PCT)
Prior art keywords
liposomes
pharmaceutical formulation
eye
active ingredient
ocular administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/052061
Other languages
French (fr)
Other versions
WO2011098578A2 (en
Inventor
Daniel Bar-Shalom
Simon SKJØDE JENSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioneer AS
Original Assignee
Bioneer AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioneer AS filed Critical Bioneer AS
Publication of WO2011098578A2 publication Critical patent/WO2011098578A2/en
Publication of WO2011098578A3 publication Critical patent/WO2011098578A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention concerns a pharmaceutical formulation for ocular or intra-ocular administration providing sustained or delayed release of at least one active ingredient, said pharmaceutical formulation comprising liposomes, said liposomes comprising at least part of said at least one active ingredient, at least part of said liposomes exhibiting a charge increasing the adherence of the charged liposomes to the eye after administration, in particular when said pharmaceutical formulation is for ocular administration, and wherein at least one of the lipids in the liposomes is degradable by sPLA2 activity, allowing sustained or delayed release of said at least one active ingredient from said liposomes upon contact with tear fluid or with sPLA2 in the eye or in the vicinity of the eye. The pharmaceutical formulation is useful for ophthalmic indications.
PCT/EP2011/052061 2010-02-12 2011-02-11 Liposome system for ocular administration Ceased WO2011098578A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30375810P 2010-02-12 2010-02-12
US61/303,758 2010-02-12
DKPA201070051 2010-02-12
DKPA201070051 2010-02-12

Publications (2)

Publication Number Publication Date
WO2011098578A2 WO2011098578A2 (en) 2011-08-18
WO2011098578A3 true WO2011098578A3 (en) 2011-10-20

Family

ID=44280689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/052061 Ceased WO2011098578A2 (en) 2010-02-12 2011-02-11 Liposome system for ocular administration

Country Status (1)

Country Link
WO (1) WO2011098578A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
WO2012021107A2 (en) * 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
EP2638896A1 (en) * 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
US9630909B2 (en) 2013-06-27 2017-04-25 Mylan Laboratories Ltd Process for the preparation of nepafenac
US9956195B2 (en) * 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
WO2016048242A1 (en) * 2014-09-24 2016-03-31 Nanyang Technological University Sustained timolol maleate delivery from liposomes for glaucoma therapy and ocular hypertension
WO2016046640A2 (en) 2014-09-26 2016-03-31 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
CN118453493A (en) 2015-05-29 2024-08-09 西德奈克西斯公司 D2O-stabilized pharmaceutical preparations
WO2017027017A1 (en) * 2015-08-11 2017-02-16 Peregrine Ophthalmic PTE LTD. Stable liposomal formulations of carbonic anhydrase inhibitors for ocular drug delivery
US20170119666A1 (en) * 2015-10-29 2017-05-04 Peregrine Ophthalmic PTE LTD. Stable liposomal formulations of alpha 2 adrenergic agonists for ocular delivery
SG11201809136UA (en) * 2016-04-19 2018-11-29 Univ Nanyang Tech Subconjuctival depot forming formulations for ocular drug delivery
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
AU2018283250B2 (en) 2017-06-16 2022-09-01 The Doshisha mTOR-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
WO2019071245A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. Implantable depots for controlled release of analgesics to treat postoperative pain associated with orthopedic surgery, and associated devices, systems, and methods
CN107982219B (en) * 2017-11-30 2020-09-15 天津中医药大学 Cationic modified pilocarpine hydrochloride flexible nanoliposome ophthalmic preparation and preparation method
WO2019136490A1 (en) 2018-01-08 2019-07-11 Foundry Therapeutics, Inc. Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents
US12458589B2 (en) 2018-05-12 2025-11-04 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
US12303619B2 (en) 2018-08-28 2025-05-20 Foundry Therapeutics, Inc. Polymer implants
CN113244171A (en) * 2021-01-28 2021-08-13 周斌 Timolol maleate liposome gel and preparation method thereof
US12153287B2 (en) * 2022-09-27 2024-11-26 Coopervision International Limited Sustained fatty acid release from contact lens
US20240118559A1 (en) 2022-09-27 2024-04-11 Coopervision International Limited Sustained release of oleic acid from contact lenses
WO2025129271A1 (en) * 2023-12-22 2025-06-26 The University Of Queensland Lipid delivery vehicle
CN117643573B (en) * 2024-01-29 2024-05-03 天津医科大学眼科医院 Nano eye drops capable of delivering drugs to the posterior segment of the eye, preparation method thereof, and application thereof
WO2025212563A1 (en) * 2024-04-02 2025-10-09 The Children's Medical Center Corporation Injectable hydrogel based on liposome self-assembly for sustained release of small hydrophilic molecules

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) * 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US5665770A (en) * 1993-11-05 1997-09-09 Gakko Hojin Kinki Daigaku Method for treatment of cataract with radical scavenger
US20040224010A1 (en) * 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0651638B2 (en) 1989-02-13 1994-07-06 新技術事業団 Eye drops for corneal epithelial wound treatment
ES2230268T3 (en) 2000-02-10 2005-05-01 Liplasome Pharma A/S LIBERATION SYSTEM OF LIPID BASED PHARMACOS.
EP2004236A2 (en) 2006-03-23 2008-12-24 Liplasome Pharma A/S Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804539A (en) * 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) * 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US5665770A (en) * 1993-11-05 1997-09-09 Gakko Hojin Kinki Daigaku Method for treatment of cataract with radical scavenger
US20040224010A1 (en) * 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AL-MUHAMMED J ET AL: "IN-VIVO STUDIES ON DEXAMETHASONE SODIUM PHOSPHATE LIPOSOMES", JOURNAL OF MICROENCAPSULATION, vol. 13, no. 3, 1 January 1996 (1996-01-01), TAYLOR AND FRANCIS, BASINGSTOKE, GB, pages 293 - 305, XP009000577, ISSN: 0265-2048 *
LAW S L ET AL: "Acyclovir-containing liposomes for potential ocular delivery - Corneal penetration and absorption", JOURNAL OF CONTROLLED RELEASE, vol. 63, no. 1-2, 1 January 2000 (2000-01-01), ELSEVIER, AMSTERDAM, NL, pages 135 - 140, XP004185078, ISSN: 0168-3659, DOI: 10.1016/S0168-3659(99)00192-3 *
SCHAEFFER H E ET AL: "LIPOSOMES IN TOPICAL DRUG DELIVERY", INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, vol. 22, no. 2, 1982, pages 220 - 227, XP002654442, ISSN: 0146-0404 *

Also Published As

Publication number Publication date
WO2011098578A2 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
WO2011098578A3 (en) Liposome system for ocular administration
de la Fuente et al. Chitosan-based nanostructures: a delivery platform for ocular therapeutics
WO2012071476A3 (en) Drug eluting ocular implant
Das et al. Lipid-based nanocarriers for ocular drug delivery: An updated review
HK1198631A1 (en) Prevention and treatment of ocular conditions
WO2010068281A3 (en) Contact lens drug delivery device
WO2012091523A8 (en) Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof
WO2012002640A3 (en) Transdermal drug delivery system containing donepezil
WO2015095772A3 (en) Formulations and methods for targeted ocular delivery of therapeutic agents
WO2012021107A3 (en) A liposomal formulation for ocular drug delivery
HK1211867A1 (en) Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
WO2014165308A3 (en) Microsphere drug delivery system for sustained intraocular release
WO2011091205A3 (en) Intracameral sustained release therapeutic agent implants
WO2013036309A3 (en) Sustained release formulations for delivery of proteins to the eye and methods of preparing same
WO2010146591A3 (en) Methods and devices for delivery of pharmaceutical agents within orifices of the body
WO2011151685A8 (en) N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament
JP2012533517A5 (en)
IN2014CN03123A (en)
MX2013000661A (en) Eye drug delivery system.
WO2015023884A3 (en) Timed release of substances to treat ocular disorders
HK1231376A1 (en) Topical formulations and uses thereof
MY203280A (en) Ursodeoxycholic acid-containing agent for treating or preventing presbyopia
WO2012163827A3 (en) Ophthalmic preparation comprising a pgf2alpha analogue
WO2011076368A3 (en) Topical ophthalmic peptide formulation
WO2008027793A3 (en) Ophthalmic pharmaceutical compositions and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11702670

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11702670

Country of ref document: EP

Kind code of ref document: A2